Zymedi Venture Capital
2 known investors
ZYMEDI is a drug discovery company that partners through R&D joint ventures, strategic investments, and in-licensing arrangements. It works with collaborators across the pharmaceutical and biotechnology sector.
Investors · 2
Company profile
researched Aug 2026ZYMEDI is a drug discovery company focused on precision medicine for life-threatening diseases that lack a standard of care or effective treatment options. Its scientific approach centers on aminoacyl-tRNA synthetases (ARSs), enzymes that charge amino acids onto their corresponding tRNA molecules as the first step of protein synthesis. Rather than targeting the canonical catalytic activity of these enzymes, ZYMEDI works from the premise that ARSs also carry out noncatalytic regulatory functions important to maintaining physiological homeostasis, and that these functions have pathological relevance in cancer, immune disorders and neurological diseases.
On that basis, the company positions ARSs both as novel therapeutic targets and as a source of therapeutic modalities, and states that its platform supports a pipeline of first-in-class drug candidates for difficult-to-treat conditions. The company presents its work across science, platform, solution and approach, and highlights team expertise in ARS biology as a core asset.
Business model
ZYMEDI describes itself as open to joint ventures, strategic investors and in-licensing partners, indicating that it pursues drug discovery collaborations and partnered development alongside its internal pipeline.
▸Full profile — market position, technology, go-to-market
Market position
ZYMEDI operates in precision medicine and first-in-class drug discovery, differentiating on ARS biology as an emerging target class rather than competing within established target families.
Technology
The company's technology is built on the biology of aminoacyl-tRNA synthetases (ARSs). ARSs perform the catalytic step of attaching amino acids to tRNA during translation, but ZYMEDI focuses on their additional noncatalytic regulatory roles in homeostasis. It uses these regulatory functions to define new drug targets and therapeutic modalities, applying them to indications including cancer, immune disorders and neurological disease.
Go-to-market
The company solicits partnership inquiries directly, inviting joint ventures, strategic investors and in-licensing partners to engage with it on programs for hard-to-treat disease areas.
Pharmaceutical and biotechnology counterparties, including prospective joint venture collaborators, strategic investors and in-licensing partners.
Compiled by commissioned research from 2 cited public sources — announcements, filings, and press listed under research sources below.
▸Research sources · 2
primary sources listed
- Zymedi Venture Capitalzymedi.com · web
2 public sources were cited for this profile; the first-party ones are listed here.
Frequently asked questions
- What does Zymedi Venture Capital do?
- ZYMEDI is a drug discovery company developing first-in-class precision medicines based on aminoacyl-tRNA synthetase (ARS) biology.
- Who are Zymedi Venture Capital's investors?
- Zymedi Venture Capital's investors include Atinum Investment Co. Ltd., IMM Investment Japan.